Invention Grant
- Patent Title: Duocarmycin ADCs for use in treatment of endometrial cancer
-
Application No.: US15216366Application Date: 2016-07-21
-
Publication No.: US10092659B2Publication Date: 2018-10-09
- Inventor: Alessandro Davide Santin , Peter Johannes Goedings
- Applicant: Synthon Biopharmaceuticals B.V. , Yale University
- Applicant Address: NL Nijmegen US CT New Haven
- Assignee: Synthon Biopharmaceuticals B.V.,Yale University
- Current Assignee: Synthon Biopharmaceuticals B.V.,Yale University
- Current Assignee Address: NL Nijmegen US CT New Haven
- Agency: Sterne, Kessler, Goldstein & Fox P.L.L.C.
- Priority: EP14150791 20140110
- Main IPC: A61K47/68
- IPC: A61K47/68 ; A61K31/5517 ; A61K47/48 ; A61K39/395 ; A61K45/06 ; C07K16/40 ; A61K9/00 ; C07K16/30 ; C07K16/32 ; A61K47/65 ; A61K39/00
Abstract:
The present invention relates to duocarmycin-containing antibody-drug conjugates (ADCs) for use in the treatment of human solid tumors expressing HER2, wherein the human solid tumor expressing HER2 is endometrial cancer, in particular uterine serous carcinoma (USC). In particular, the present invention relates to duocarmycin-containing ADCs for use in the treatment of endometrial cancer, notably USC, with HER2 IHC 2− or 1+ and HER2 FISH negative tumor tissue status.
Public/Granted literature
- US20170007717A1 DUOCARMYCIN ADCS FOR USE IN TREATMENT OF ENDOMETRIAL CANCER Public/Granted day:2017-01-12
Information query
IPC分类:
